Polyamines are small molecules produced by all living cells. They help with essential functions, like cell growth and specialization. Recently, researchers have become particularly interested in spermidine, a type of polyamine, because it may support healthy aging. It acts as a “geroprotector” by promoting autophagy, a process that clears out damaged cell parts. This process is largely facilitated by a protein called eukaryotic translation initiation factor 5A1 (eIF5A1).
Interestingly, high levels of polyamines are also found in various cancers, where they seem to encourage aggressive tumor growth. This leads to a scientific mystery: how can compounds that seem to promote longevity also be associated with cancer?
The link between polyamines and cancer isn’t new, but the details are still unclear. Cancer cells change their metabolism, using a process called aerobic glycolysis to create energy quickly. The exact role of polyamines in this switch has not been well defined yet.
Adding to the complexity, eIF5A1 functions normally in healthy cells, while a closely related protein, eIF5A2, has been tied to cancer. Why these two similar proteins react so differently is a key question in research.
To explore this, a team at Tokyo University of Science, led by Associate Professor Kyohei Higashi, conducted a detailed study utilizing advanced molecular and proteomic methods. They examined human cancer cell lines to see how polyamines affect protein production and metabolism. Researchers first reduced polyamine levels, then added spermidine back, allowing them to observe the effects on cancer cells.
Their study looked at over 6,700 proteins and found that polyamines mainly boost glycolysis rather than support the healthy mitochondrial respiration that’s often linked to aging. They noticed that polyamines increase eIF5A2 and certain ribosomal proteins associated with cancer severity.
A side-by-side analysis of eIF5A1 and eIF5A2 offered vital insights. According to Dr. Higashi, “The biological activity of polyamines via eIF5A differs between normal and cancer tissues.” In healthy cells, eIF5A1 helps activate the mitochondria through autophagy. In contrast, in cancer cells, eIF5A2, boosted by polyamines, regulates gene expression to aid rapid growth.
Moreover, researchers identified how polyamines increase eIF5A2 levels. Normally, a small regulatory RNA molecule, miR-6514-5p, keeps eIF5A2 production in check. Polyamines disrupt this regulation, boosting eIF5A2 levels and reinforcing that eIF5A1 and eIF5A2 serve distinct functions.
These findings have important implications. They highlight that the effects of polyamines largely depend on the biological context. In healthy cells, they may provide anti-aging benefits, while in cancerous cells, they could stimulate growth. This dual behavior complicates how polyamines are viewed in medical research.
The study also opens new potential avenues for cancer therapy. “Our findings suggest that targeting eIF5A2, regulated by polyamines and miR-6514-5p, could slow cancer growth,” Dr. Higashi noted. Such targeting might slow tumor growth without hindering the positive effects of eIF5A1.
This research is a significant step in understanding the complex roles of polyamines. In the long run, it could lead to strategies that harness the benefits of polyamines for healthy aging while minimizing their linkage to cancer.
For more insights, you can check the study published in the Journal of Biological Chemistry.
Source link
Pharmacology; Pharmaceuticals; Gene Therapy; Today's Healthcare; Fitness; Personalized Medicine; Diseases and Conditions; Genes
